TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2993892

Group type: EXPERIMENTAL
Intervention: Aftercare program; includes a comprehensive 6-month training curriculum and self-help fellowship meetings.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual-care control condition; details not specified.
Number of subjects: 0
Study: 30693094

Group type: EXPERIMENTAL
Intervention: Usual care + peer befriending
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study: 28958125

Group type: EXPERIMENTAL
Intervention: Culture-sensitive patient information materials (PIM)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Standard translated material
Number of subjects: 29
Study: 29465890

Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Propofol anesthesia
Number of subjects: 60
Study: 23671001

Group type: EXPERIMENTAL
Intervention: Resident Assessment Instrument (RAI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Optimal RAI users
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Suboptimal RAI users
Number of subjects: 0
Study: 22891797

Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC) 2 g/day as adjunct maintenance treatment
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study: 20451687

Group type: EXPERIMENTAL
Intervention: Mipomersen 200 mg/week
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Mipomersen 300 mg/week
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 17094172

Group type: EXPERIMENTAL
Intervention: Water extract of Hibiscus sabdariffa (300 mL daily for 3 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no beverage)
Number of subjects: 0
Study: 18598992

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complete endoscopic healing in response to infliximab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conventional treatments with distal colonoscopy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-viral treatment added to conventional treatments
Number of subjects: 0
Study: 15309458

Group type: EXPERIMENTAL
Intervention: Cooked cherry tomatoes
Number of subjects: 5

Group type: COMPARATOR
Intervention: Fresh cherry tomatoes
Number of subjects: 5
Study: 11769605

Group type: EXPERIMENTAL
Intervention: Medium-chain triglyceride (MCT) emulsion
Number of subjects: 30

Group type: COMPARATOR
Intervention: Long-chain triglyceride (LCT) emulsion
Number of subjects: 30
Study: 9362378

Group type: EXPERIMENTAL
Intervention: IL-2 0.9 MIU
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: IL-2 1.8 MIU
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: IL-2 3.6 MIU
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: IL-2 5.4 MIU
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: IL-2 treatment overall
Number of subjects: 33
Study: 8213871

Group type: EXPERIMENTAL
Intervention: Teaching group (eight-session physical diagnosis course on the cardiology-patient simulator 'Harvey')
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (no supplemental teaching)
Number of subjects: 56
Study: 3777458

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Number of subjects: 44
Study: 11915784

Group type: EXPERIMENTAL
Intervention: HIGH CHO diet (greater than 70% of daily energy intake from CHO)
Number of subjects: 7

Group type: COMPARATOR
Intervention: LOW CHO diet (less than 10% of daily energy intake from CHO)
Number of subjects: 7
Study: 31768402

Group type: EXPERIMENTAL
Intervention: Enhanced First Breath program (4 in-home counseling visits, 3 postpartum counseling calls, support to others in the home, incentives totaling $100)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Standard First Breath program (control group)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Enhanced First Breath program (intent-to-treat analysis)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Standard First Breath program (intent-to-treat analysis)
Number of subjects: 185
Study: 29198623

Group type: EXPERIMENTAL
Intervention: Video-assisted thoracoscopic surgery (VATS)
Number of subjects: 425

Group type: COMPARATOR
Intervention: Axillary thoracotomy
Number of subjects: 425
Study: 27588816

Group type: EXPERIMENTAL
Intervention: AndoSanTM
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 24686911

Group type: EXPERIMENTAL
Intervention: High cue condition
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Low cue condition
Number of subjects: 8
Study: 22585590

Group type: EXPERIMENTAL
Intervention: Paliperidone ER (6 mg)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Risperidone (3 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 19833898

Group type: EXPERIMENTAL
Intervention: Indirect self-affirmations following intelligence threats
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Direct self-affirmations following belonging threats
Number of subjects: 4

Group type: COMPARATOR
Intervention: Indirect affirmation strategies
Number of subjects: 4
Study: 17376267

Group type: EXPERIMENTAL
Intervention: Rhubarb preventive treatment group (3.0%)
Number of subjects: 1090

Group type: EXPERIMENTAL
Intervention: Enteral nutrition support subgroup (0.9%)
Number of subjects: 1090

Group type: EXPERIMENTAL
Intervention: Enteral combined parenteral nutrition support subgroup (2.1%)
Number of subjects: 1090

Group type: COMPARATOR
Intervention: Parenteral nutrition support subgroup
Number of subjects: 1090

Group type: COMPARATOR
Intervention: No nutrition support subgroup
Number of subjects: 1090
Study: 15946863

Group type: EXPERIMENTAL
Intervention: Continuous self-reported rating of emotion experience
Number of subjects: 0

Group type: COMPARATOR
Intervention: Passive viewing of amusing and sad films
Number of subjects: 0
Study: 12030958

Group type: EXPERIMENTAL
Intervention: Double dose of proton pump inhibitor
Number of subjects: 2391

Group type: COMPARATOR
Intervention: Single dose of proton pump inhibitor
Number of subjects: 2391
Study: 12669740

Group type: EXPERIMENTAL
Intervention: Alendronate therapy
Number of subjects: 0
Study: 7770713

Group type: EXPERIMENTAL
Intervention: Standard ORS containing bicarbonate
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bicarbonate-free ORS
Number of subjects: 60
Study: 2189319

Group type: EXPERIMENTAL
Intervention: New formulation of intranasal flunisolide (0.025% solution, 200 micrograms daily for 4 weeks)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Original formulation of intranasal flunisolide (0.025% solution, 200 micrograms daily for 4 weeks)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: New formulation of intranasal flunisolide
Number of subjects: 200

Group type: COMPARATOR
Intervention: Original formulation of intranasal flunisolide
Number of subjects: 200
Study: 43164

Group type: EXPERIMENTAL
Intervention: Atenolol (138 +/- 13 mg daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metoprolol (234 +/- 22 mg daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pindolol (24 +/- 2 mg daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Labetalol (308 +/- 34 mg daily)
Number of subjects: 0
Study: 30777131

Group type: EXPERIMENTAL
Intervention: High-dose Interleukin-2 (HD IL-2)
Number of subjects: 57
Study: 30101539

Group type: EXPERIMENTAL
Intervention: RPV/FTC/TAF
Number of subjects: 1505

Group type: COMPARATOR
Intervention: RPV/FTC/TDF
Number of subjects: 1505

Group type: COMPARATOR
Intervention: EFV/FTC/TDF
Number of subjects: 1505
Study: 26758744

Group type: EXPERIMENTAL
Intervention: LLINs + IRS
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: LLINs alone
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: IRS alone
Number of subjects: 770

Group type: COMPARATOR
Intervention: Control
Number of subjects: 770
Study: 25245491

Group type: EXPERIMENTAL
Intervention: Referral self-efficacy
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Perceived referral norms
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Referral anticipatory anxiety
Number of subjects: 317

Group type: COMPARATOR
Intervention: Length of RA service and time spent on campus
Number of subjects: 317
Study: 23003122

Group type: COMPARATOR
Intervention: 3-W laser beam for 10 sec (Group 2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 1% sodium hypochlorite for 15 min (Group 4)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1% sodium hypochlorite for 15 min followed by 3-W laser beam for 10 sec (Group 3)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (Group 1)
Number of subjects: 60
Study: 20062915

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 5mg
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10mg
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20mg
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 30mg
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 40mg
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (all doses)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 17432678

Group type: EXPERIMENTAL
Intervention: Shenfu Injection (SF) 1 mL/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Shenfu Injection (SF)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 24
Study: 15632922

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided percutaneous closed drainage
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Indwelling catheter (only 8 patients had this intervention)
Number of subjects: 14
Study: 14571614

Group type: EXPERIMENTAL
Intervention: Luohuo Capsule (LHC)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Beijing Hypotensive No. 0 (Control)
Number of subjects: 90
Study: 10973392

Group type: EXPERIMENTAL
Intervention: Octreotide 250 microg subcutaneously every 8 hours for 7 days
Number of subjects: 211

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 211
Study: 8804239

Group type: EXPERIMENTAL
Intervention: Subcutaneous (s.c.) recombinant erythropoietin (rH-EPO)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Intravenous (i.v.) recombinant erythropoietin (rH-EPO)
Number of subjects: 49
Study: 1536396

Group type: EXPERIMENTAL
Intervention: Fentanyl 6 micrograms.kg‐1 during fibreoptic intubation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fentanyl 6 micrograms.kg‐1 during Macintosh intubation
Number of subjects: 60
Study: 6376918

Group type: EXPERIMENTAL
Intervention: Low-phosphorus, low-protein diet (7.0 mg phosphorus and 0.5 g protein per kg body weight)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control diet (12 mg phosphorus and 0.8 g protein per kg body weight)
Number of subjects: 20
Study: 30576781

Group type: EXPERIMENTAL
Intervention: Composite Dietary Antioxidant Index (CDAI)
Number of subjects: 894

Group type: EXPERIMENTAL
Intervention: Zinc intake
Number of subjects: 894

Group type: EXPERIMENTAL
Intervention: Vitamin E intake
Number of subjects: 894

Group type: EXPERIMENTAL
Intervention: Age, systolic blood pressure, and triglycerides as predictors
Number of subjects: 894

Group type: COMPARATOR
Intervention: CDAI in men
Number of subjects: 894
Study: 29573473

Group type: EXPERIMENTAL
Intervention: Romosozumab 210 mg s.c. once monthly for 12 months
Number of subjects: 7180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7180
Study: 27483318

Group type: EXPERIMENTAL
Intervention: Fluid-specific questionnaire for assessing water intake from beverages
Number of subjects: 160

Group type: COMPARATOR
Intervention: Baseline measurement
Number of subjects: 160
Study: 24774860

Group type: EXPERIMENTAL
Intervention: Calcitriol supplementation (0.5 μg/day for one year)
Number of subjects: 484

Group type: COMPARATOR
Intervention: Control group (patients without depression)
Number of subjects: 484
Study: 22476724

Group type: EXPERIMENTAL
Intervention: Frequency discrimination training with a pure-tone standard at a frequency within their region of normal hearing
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Frequency discrimination training with a pure-tone standard within the region of hearing loss
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Frequency discrimination training with a high-pass harmonic complex tone spanning a region of hearing loss
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 70
Study: 21244729

Group type: EXPERIMENTAL
Intervention: Articaine
Number of subjects: 70

Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 70
Study: 17920715

Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiotherapy (HF) - 58 Gy in 40 equal fractions given twice per day
Number of subjects: 331

Group type: COMPARATOR
Intervention: Conventional fractionation (CF) - 51 Gy in 20 equal daily fractions
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiotherapy (HF)
Number of subjects: 331

Group type: COMPARATOR
Intervention: Conventional fractionation (CF)
Number of subjects: 331
Study: 16033855

Group type: EXPERIMENTAL
Intervention: Short daily hemodialysis (6 sessions/wk of 3 h each)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Conventional hemodialysis (three sessions/wk of 4 h each)
Number of subjects: 77
Study: 12241539

Group type: EXPERIMENTAL
Intervention: Noradrenaline infusion (0.147 nmol.min(‐1).kg(‐1))
Number of subjects: 16

Group type: COMPARATOR
Intervention: Emagel infusion (control)
Number of subjects: 16
Study: 9737807

Group type: EXPERIMENTAL
Intervention: Troglitazone 400 mg once daily
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Troglitazone 200 mg twice daily
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Troglitazone 800 mg once daily
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Troglitazone 400 mg twice daily
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Troglitazone (all doses)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229
Study: 7802188

Group type: EXPERIMENTAL
Intervention: Machine A (AVL 912 co-oxylite co-oximeter)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Machine B (AVL 912 co-oxylite co-oximeter)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Machine C (IL-282 co-oximeter)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Machines A and B (AVL 912 co-oxylite co-oximeters)
Number of subjects: 96
Study: 3188983

Group type: EXPERIMENTAL
Intervention: Pinacidil
Number of subjects: 131

Group type: COMPARATOR
Intervention: Prazosin
Number of subjects: 131
Study: 30846389

Group type: EXPERIMENTAL
Intervention: Resistance training using elastic tubing (GET)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Conventional resistance training (GCT)
Number of subjects: 28
Study: 29986720

Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Non-Ketogenic diet (NKD)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 24
Study: 25795907

Group type: EXPERIMENTAL
Intervention: tofacitinib 10 mg twice daily
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: continuous tofacitinib 10 mg twice daily
Number of subjects: 383

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: withdrawn tofacitinib
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: continuous tofacitinib
Number of subjects: 383
Study: 25239484

Group type: EXPERIMENTAL
Intervention: 0.5 mL vaccine subcutaneously at days 0, 14
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 0.5 mL vaccine subcutaneously at days 0 and 28
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 0.5 mL vaccine subcutaneously at days 0, 14, and 28
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 0.25 mL vaccine subcutaneously at days 0, 14, and 28
Number of subjects: 100
Study: 22348304

Group type: COMPARATOR
Intervention: Diclofenac suppository (100 mg) plus saline 0.9% (placebo)
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Diclofenac suppository (100 mg) plus intravenous papaverine hydrochloride (1.5 mg/kg up to 120 mg)
Number of subjects: 550
Study: 19394643

Group type: EXPERIMENTAL
Intervention: Non-drained group
Number of subjects: 101

Group type: COMPARATOR
Intervention: Drained group
Number of subjects: 101
Study: 17542768

Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray
Number of subjects: 0
Study: 15533540

Group type: EXPERIMENTAL
Intervention: High intensity intervention group (smoking cessation groups)
Number of subjects: 2168
Study: 11896091

Group type: EXPERIMENTAL
Intervention: Soy beverage containing 90 mg of isoflavones
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo rice beverage
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Soy beverage
Number of subjects: 123
Study: 9808483

Group type: EXPERIMENTAL
Intervention: Daily oral clodronate (800 mg)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Daily intranasal calcitonin (200 IU)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no specific treatment mentioned)
Number of subjects: 46
Study: 7663595

Group type: EXPERIMENTAL
Intervention: Standardized pain flowsheet documentation
Number of subjects: 61

Group type: COMPARATOR
Intervention: Traditional charting of pain presence or absence
Number of subjects: 61
Study: 2521333

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic factor (0.025 microgram/kg/min)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Isoproterenol (0.02 microgram/kg/min)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Furosemide (5 mg i.v. bolus)
Number of subjects: 7
Study: 1061652

Group type: EXPERIMENTAL
Intervention: 2% sodium monofluorophosphate dentifrice
Number of subjects: 1407
Study: 7262760

Group type: EXPERIMENTAL
Intervention: Lidaprim (combination of sulfametrol and trimethoprim)
Number of subjects: 29
Study: 30678256

Group type: EXPERIMENTAL
Intervention: Mother’s own milk (MOM) supplements of preterm formula
Number of subjects: 321

Group type: COMPARATOR
Intervention: Fortified donor breastmilk (DM)
Number of subjects: 321
Study: 28914247

Group type: EXPERIMENTAL
Intervention: Nitrous oxide (N2O)‐oxygen (O2) inhalation sedation using preadjusted mix of 30% N2O and 70% O2 through rapid induction technique
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional slow induction technique
Number of subjects: 60
Study: 27128005

Group type: EXPERIMENTAL
Intervention: Extemporaneous preparation suspension (EP; 10 mg/mL)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Crushed sildenafil 20 mg tablet mixed with apple sauce
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Intact sildenafil 20 mg tablet
Number of subjects: 18
Study: 23628755

Group type: EXPERIMENTAL
Intervention: Manual therapy and exercise (MTEX)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Home exercise program (HEP)
Number of subjects: 74
Study: 22480173

Group type: EXPERIMENTAL
Intervention: Resection of the primary tumour prior to systemic chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Systemic chemotherapy without resection of the primary tumour
Number of subjects: 0
Study: 19365388

Group type: EXPERIMENTAL
Intervention: Cymbalta (antidepressant, serotonin and noradrenalin reuptake inhibitor)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Cymbalta
Number of subjects: 29
Study: 17689883

Group type: EXPERIMENTAL
Intervention: Short-term androgen deprivation (STAD) + radiation therapy (RT)
Number of subjects: 777

Group type: EXPERIMENTAL
Intervention: Abnormal p53 status
Number of subjects: 777

Group type: EXPERIMENTAL
Intervention: Abnormal p53 expression
Number of subjects: 777
Study: 15006116

Group type: EXPERIMENTAL
Intervention: Men aged 70-74
Number of subjects: 34000

Group type: EXPERIMENTAL
Intervention: Men in the most deprived quartile
Number of subjects: 34000
Study: 11433832

Group type: EXPERIMENTAL
Intervention: Ifenprodil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baclofen
Number of subjects: 0
Study: 9581695

Group type: EXPERIMENTAL
Intervention: Thymosin alpha1 (Talpha) 1.6 mg subcutaneous injection two times a week for 26 weeks (T6 group)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Thymosin alpha1 (Talpha) 1.6 mg subcutaneous injection two times a week for 52 weeks (T12 group)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (T0 group) followed up for 18 months without specific treatment
Number of subjects: 98
Study: 8114857

Group type: EXPERIMENTAL
Intervention: Low-protein diet (1.3 or 0.58 g of protein per kg per day)
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Low-blood-pressure group (mean arterial pressure, 92 mm Hg)
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Very-low-protein diet (0.28 g per kg per day)
Number of subjects: 840

Group type: COMPARATOR
Intervention: Low-protein diet (0.58 g per kg per day)
Number of subjects: 840

Group type: COMPARATOR
Intervention: Usual-protein diet
Number of subjects: 840

Group type: COMPARATOR
Intervention: Usual-blood-pressure group (mean arterial pressure, 107 mm Hg)
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Low-blood-pressure group with pronounced proteinuria at baseline
Number of subjects: 840
Study: 3404450

Group type: EXPERIMENTAL
Intervention: Ultra-low yield cigarettes (0.1, 0.4, 0.7 mg nicotine)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Usual-brand high-yield cigarettes (1.0, 1.1 mg nicotine)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low-yield cigarettes
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: All yield conditions
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ultra-low yield cigarettes
Number of subjects: 10
Study: 31732700

Group type: EXPERIMENTAL
Intervention: New Medicine Service (NMS)
Number of subjects: 504

Group type: COMPARATOR
Intervention: Normal practice (Control)
Number of subjects: 504
Study: 30419974

Group type: EXPERIMENTAL
Intervention: Paleolithic diet
Number of subjects: 39

Group type: COMPARATOR
Intervention: Australian Guide to Healthy Eating (AGHE) diet
Number of subjects: 39
Study: 29023611

Group type: EXPERIMENTAL
Intervention: Autologous platelet-rich fibrin (PRF) combined with modified flap operation (MFO; Kirkland flap)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Modified flap operation (MFO; Kirkland flap) alone
Number of subjects: 15
Study: 26071796

Group type: EXPERIMENTAL
Intervention: Tigatuzumab (6 mg/kg loading, 2 mg/kg/week maintenance) plus sorafenib 400 mg twice daily
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Tigatuzumab (6 mg/kg loading, 6 mg/kg/week maintenance) plus sorafenib 400 mg twice daily
Number of subjects: 163

Group type: COMPARATOR
Intervention: Sorafenib 400 mg twice daily
Number of subjects: 163